{"title":"脑胶质瘤术后患者血清GFAP和3-NT水平与神经元损伤程度的相关性及其诊断价值","authors":"Jiaode Jiang, Feng Liu","doi":"10.1080/17520363.2025.2559432","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the correlation between postoperative serum glial fibrillary acidic protein (GFAP) and 3-nitrotyrosine (3-NT) levels and neuronal injury severity in glioma patients.</p><p><strong>Methods: </strong>150 glioma patients were enrolled, with clinical baseline and pathological data recorded (age, sex, etc.). Neuronal injury was assessed using the National Institutes of Health Stroke Scale (NIHSS) postoperatively, categorizing patients into mild (NIHSS 1 ~ 4, <i>n</i> = 54) and moderate-to-severe (NIHSS ≥5, <i>n</i> = 96) groups. Serum GFAP and 3-NT levels were measured three days post-surgery via ELISA. Correlations with NIHSS were analyzed with Spearman's test. Patients were also stratified by median biomarker levels. Multivariate logistic regression identified severity risk factors. Receiver operating characteristic (ROC) curves evaluated diagnostic value.</p><p><strong>Results: </strong>GFAP and 3-NT levels were higher in the moderate-to-severe group (<i>p</i> < 0.001) and positively correlated with NIHSS scores (GFAP: <i>r</i> = 0.552; 3-NT: <i>r</i> = 0.545). Higher biomarker levels were significantly associated with worse injury (<i>p</i> < 0.001). Both were independent risk factors for severity. Combining GFAP and 3-NT predicted severity significantly better than either alone (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Postoperative serum GFAP and 3-NT levels correlate positively with neuronal injury severity in glioma patients. Their combination provides high diagnostic value for assessing postoperative injury severity.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"837-846"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477868/pdf/","citationCount":"0","resultStr":"{\"title\":\"Correlation between serum GFAP and 3-NT levels and the degree of neuronal injury in patients with glioma after surgery, and its diagnostic value.\",\"authors\":\"Jiaode Jiang, Feng Liu\",\"doi\":\"10.1080/17520363.2025.2559432\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To investigate the correlation between postoperative serum glial fibrillary acidic protein (GFAP) and 3-nitrotyrosine (3-NT) levels and neuronal injury severity in glioma patients.</p><p><strong>Methods: </strong>150 glioma patients were enrolled, with clinical baseline and pathological data recorded (age, sex, etc.). Neuronal injury was assessed using the National Institutes of Health Stroke Scale (NIHSS) postoperatively, categorizing patients into mild (NIHSS 1 ~ 4, <i>n</i> = 54) and moderate-to-severe (NIHSS ≥5, <i>n</i> = 96) groups. Serum GFAP and 3-NT levels were measured three days post-surgery via ELISA. Correlations with NIHSS were analyzed with Spearman's test. Patients were also stratified by median biomarker levels. Multivariate logistic regression identified severity risk factors. Receiver operating characteristic (ROC) curves evaluated diagnostic value.</p><p><strong>Results: </strong>GFAP and 3-NT levels were higher in the moderate-to-severe group (<i>p</i> < 0.001) and positively correlated with NIHSS scores (GFAP: <i>r</i> = 0.552; 3-NT: <i>r</i> = 0.545). Higher biomarker levels were significantly associated with worse injury (<i>p</i> < 0.001). Both were independent risk factors for severity. Combining GFAP and 3-NT predicted severity significantly better than either alone (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Postoperative serum GFAP and 3-NT levels correlate positively with neuronal injury severity in glioma patients. Their combination provides high diagnostic value for assessing postoperative injury severity.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"837-846\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477868/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2559432\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2559432","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
目的：探讨胶质瘤患者术后血清胶质原纤维酸性蛋白（GFAP）和3-硝基酪氨酸（3-NT）水平与神经损伤严重程度的关系。方法：选取150例胶质瘤患者，记录临床基线及病理资料（年龄、性别等）。术后采用美国国立卫生研究院卒中量表（NIHSS）评估神经损伤，将患者分为轻度组（NIHSS 1 ~ 4, n = 54）和中度至重度组（NIHSS≥5,n = 96）。术后3 d采用ELISA检测血清GFAP和3-NT水平。采用Spearman检验分析与NIHSS的相关性。患者也按中位生物标志物水平分层。多变量logistic回归确定了严重程度的危险因素。受试者工作特征（ROC）曲线评价诊断价值。结果：GFAP和3-NT水平在中重度组较高（p r = 0.552; 3-NT: r = 0.545）。结论：胶质瘤患者术后血清GFAP和3-NT水平与神经元损伤严重程度呈正相关。它们的组合对评估术后损伤严重程度具有很高的诊断价值。
Correlation between serum GFAP and 3-NT levels and the degree of neuronal injury in patients with glioma after surgery, and its diagnostic value.
Objective: To investigate the correlation between postoperative serum glial fibrillary acidic protein (GFAP) and 3-nitrotyrosine (3-NT) levels and neuronal injury severity in glioma patients.
Methods: 150 glioma patients were enrolled, with clinical baseline and pathological data recorded (age, sex, etc.). Neuronal injury was assessed using the National Institutes of Health Stroke Scale (NIHSS) postoperatively, categorizing patients into mild (NIHSS 1 ~ 4, n = 54) and moderate-to-severe (NIHSS ≥5, n = 96) groups. Serum GFAP and 3-NT levels were measured three days post-surgery via ELISA. Correlations with NIHSS were analyzed with Spearman's test. Patients were also stratified by median biomarker levels. Multivariate logistic regression identified severity risk factors. Receiver operating characteristic (ROC) curves evaluated diagnostic value.
Results: GFAP and 3-NT levels were higher in the moderate-to-severe group (p < 0.001) and positively correlated with NIHSS scores (GFAP: r = 0.552; 3-NT: r = 0.545). Higher biomarker levels were significantly associated with worse injury (p < 0.001). Both were independent risk factors for severity. Combining GFAP and 3-NT predicted severity significantly better than either alone (p < 0.001).
Conclusion: Postoperative serum GFAP and 3-NT levels correlate positively with neuronal injury severity in glioma patients. Their combination provides high diagnostic value for assessing postoperative injury severity.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
